Gilvocarcin V (GV) (structure 2; see Fig. 1 for numbered structures), the principal product of Streptomyces griseoflavus Gö 3592 and other Streptomyces spp., is the most prominent member of a distinct class of antitumor antibiotics that share a polyketide-derived coumarin-based benzo [D] naphtho [1,2-b] pyran-6-one moiety. This small family of antitumor drugs is often referred to as gilvocarcin-type anticancer drugs (5, 10, 26, 41) . Most of these natural products possess C-glycosidically linked 6-deoxy-D-hexose moieties in the 4-position, while variants within this group exist as either furanose (structures 1 to 6, structure 13) or pyranose sugars (structures 7 to 12 and 14 to 16) (5, 27, 38, 43, 45) . Notably, BE-12406A (structure 14) and B (structure 15) (15, 25) , as well as polycarcin V (structure 16) (16) , are the only examples of 6-deoxy-L-sugars found in gilvocarcin-type compounds, with structures 14 and 15 representing the only O-glycosidically linked analogues reported so far.
GV's most likely mechanism of action is a photoactivated [2 ϩ 2] cycloaddition of its vinyl side chain with thymine residues of DNA caused by near-UV or visible blue light which results in single-strand scissions leading to covalent binding with DNA (1, 3, 9, 14, 24) . In addition, GV's activity is also attributed to a unique selective cross-linking of DNA and histone H3, a core component of the histone complex that plays an important role for DNA replication and transcription (2, 8, 22, 23, 30) . The saccharide moiety, D-fucofuranose, of GV is essential for this activity, as it is believed to facilitate binding of histone H3 (17, 18) .
Recently, we identified and characterized largely the deoxysugar biosynthetic pathway that leads to D-fucofuranose (structure 26), the sugar moiety of GV (18) . It was possible to shut down the biosynthesis of gilvocarcin's natural sugar donor through the inactivation of gilU, the 4-ketoreductase involved in the biosynthesis of GV's deoxysugar moiety. The inactivation of gilU afforded a more active gilvocarcin analogue, 4Ј-hydroxy gilvocarcin V (structure 5, 4Ј-OH GV), illustrating an inherent substrate flexibility of GilGT, the glycosyltranferase responsible for C-glycosylation in GV biosynthesis (17, 18) . Additionally, the improved bioactivity of 4Ј-OH GV over that of GV clearly demonstrated the importance of further investigations into modifying the glycosylation pattern of gilvocarcins.
In our initial attempt to probe the donor substrate flexibility of GilGT and advance the glycodiversity of gilvocarcin-type anticancer drugs, we complemented the aforementioned GilU mutant, Streptomyces lividans TK24 (cosG9B3-U Ϫ ), with various deoxysugar plasmids directing the biosynthesis of neutral deoxysugars, namely, L-olivose (pLN2) (32), L-rhamnose (pRHAM) (33), Lmycarose (pFL942) (19) , L-digitoxose (pLNBIV) (32), 4-keto-Lolivose (pKOLV), and D-oliose (pOLO). These plasmids are designed for producing specific activated deoxysugars through the combination of genes from one or more deoxysugar biosynthetic pathways, and they have been utilized in successfully altering the saccharide moieties of mithramycin, steffimycin, elloramycin, and rebeccamycin/staurosporin (4, 28, 31, 35, 36) . We were particularly interested in the attachment of L-hexose sugars, as these are rarely found in gilvocarcin-type anticancer drugs. Of the six deoxysugar plasmids tested, complementation with pLN2 and pRHAM produced new gilvocarcin analogues with D-olivosyl and L-rhamnosyl moieties, respectively.
MATERIALS AND METHODS
Microorganisms and culture conditions. All complementation experiments were carried out in the heterologous host S. lividans TK24 (13) . The mutant cosmid cosG9B3-U Ϫ was introduced into S. lividans TK24 through conjugal transfer according to standard protocols (13) (13) . Regenerated protoplasts were transferred to solid M2 agar supplemented with appropriate antibiotics. Initially, each strain was grown in 250-ml baffled Erlenmeyer flasks containing 100 ml of liquid SG medium (20 g/liter glucose, 10 g/liter soy peptone, 2 g/liter CaCO 3 , 0.001 g/liter cobalt-II chloride, pH 7.2) with appropriate antibiotics and screened for gilvocarcin analogue production using high-performance liquid chromatographymass spectrometry (HPLC-MS) as described previously (11) . Escherichia coli XL1-Blue (Stratagene) was used as the subcloning host and was grown at 37°C in lysogeny broth medium, while E. coli ET12567/pUZ8002 (21, 29) was used for conjugation. When antibiotics were required for strain selection, 50 g/ml of kanamycin, 100 g/ml of ampicillin, 50 g/ml of apramycin, and 25 g/ml of thiostrepton were used.
DNA manipulation and PCR amplification. Plasmid DNA isolations were carried out using the GeneJet plasmid miniprep kit (Fermentas). All restriction endonuclease digestions, alkaline phosphatase treatments, ligations, and other DNA manipulations were performed according to standard protocols (37) . PCR was used to amplify mtmU from Streptomyces argillaceus ATCC 12596 (mithramycin producer) using the specific oligonucleotide primer mtmU_F (5Ј-ACTA GTAGAAGGAGCGCCGTGCCCG) (SpeI site is underlined). PCR conditions were as follows: 50 ng of template DNA was mixed with 50 ng of each primer with 1.25 units of Native PFU DNA polymerase (Stratagene) in a total volume of 50 l containing 0.4 mM each deoxynucleoside triphosphate (dNTP), 2 mM MgCl 2 , and 5 l dimethyl sulfoxide (DMSO). The normal PCR thermocycler conditions were 60 s at 98°C followed by 30 cycles of 60 s at 98°C, 45 s at 65°C, and 90 s at 76°C and then 10 min at 76°C. The PCR product was gel purified using a QIAquick gel extraction kit (Qiagen), subcloned into PCR-Blunt II-TOPO (Invitrogen), and sequenced (SeqWright, Houston, TX).
Plasmid constructs. Deoxysugar plasmid pKOLV was constructed by the deletion of oleU, as a SpeI-NheI fragment, from pLN2 and then self-ligated (Table 1) . To produce pOLO, oleU from pLN2 was replaced with mtmU as a SpeI-NheI fragment.
Production, isolation, and purification of gilvocarcin analogues. Strains producing novel gilvocarcin analogues were grown as seed cultures in 250-ml baffled Erlenmeyer flasks containing 100 ml liquid SG medium, as described above, and allowed to grow at 28°C for 48 h at 250 rpm. The seed cultures of S. lividans TK24 (cosG9B3-U of fermentation at 28°C with reciprocal shaking (250 rpm), the flasks were removed and combined with celite (100 g/liter) and filtered. The mycelial cake was extracted with acetone by sonication and again filtered. The acetone was removed under vacuum, and the aqueous portion was combined with the culture broth filtrate and passed through C 18 reverse-phase silica. The column was eluted with 1-liter fractions of 0, 25, 50, 75, and 100% methanol in water. Fractions containing gilvocarcin analogues were dried and lyophilized. Further purification was obtained through high-performance liquid chromatography (HPLC) according to previously described procedures (11) . NMR analysis. The 1 H and 13 C nuclear magnetic resonance (NMR) data (Tables 2 and 3; see Table S7 in the supplemental material) were recorded on a Varian Vnmr 500 spectrometer, operating on 500 MHz ( 1 H) and 125 MHz ( 13 C), respectively, using the indicated deuterated solvents.
RESULTS

In vivo coexpression of S. lividans TK24 (cosG9B3-U
؊ ) and pLN2. The well-established deoxysugar plasmid pLN2 is responsible for producing the TDP-activated 2,6-dideoxy-hexopyranose, TDP-L-olivose (structure 29) (32) . The biosynthesis of TDP-L-olivose involves two unique 2,6-dideoxy-4-ketosugar intermediates, one in D-and the other in L-configuration, which can further be reduced to TDP-D-or TDP-L-olivose. In addition, the ketosugars themselves may also serve as acceptable donor substrates for GilGT (Fig. 2) , as was shown previously for the 4-keto-D-fucofuranose (18) .
Fermentation of the recombinant mutant strain S. lividans TK24 (cosG9B3-U Ϫ /pLN2) accumulated three new peaks, structures 19, 20, and 21 (Fig. 3b) . Large-scale fermentation and preparative HPLC were used to isolate the new compounds, which were structurally characterized through NMR spectroscopy and mass spectrometry. A 60-liter fermentation of S. lividans TK24 (cosG9B3-U Ϫ /pLN2) afforded 4 mg of the major peak, D-olivosyl-gilvocarcin M (structure 19; ϳ0.07 mg/ liter). MALDI-TOF (matrix-assisted laser desorption ionization-time of flight) high-resolution mass spectrometry of structure 19 (Fig. 4A) . From HMBC correlations, we found clear evidence of C-glycosidic attachment at the C-4 position VOL. 77, 2011 GENERATION OF NOVEL GILVOCARCIN ANALOGUES 437 ( 2 J C-H coupling between 1Ј-H and C-4), while the typical 4 C 1 -conformation of D-sugars was confirmed through NOESY correlations between 1Ј-H, 3Ј-H, and 5Ј-H and between 2Ј-H a and 4Ј-H (Fig. 4B) . Assuming GilGT belongs to the GT-1 family of inverting glycosyltransferases (6, 7, 42) , the use of TDP-Dolivose as a donor substrate should result in a glycosidic bond with ␤-D-configuration, as evident from the large coupling constant of C-1Ј (␦ 5.63, J ϭ 10.5 Hz).
The remaining minor compounds were identified as D-olivosyl-gilvocarcin V (structure 20; ϳ0.05 mg/liter) and D-olivosyl-gilvocarcin E (structure 21; ϳ0.01 mg/liter). As before, structural elucidation of structure 20 was carried out through NMR (Table 3) (structures 1 to 3) are naturally produced as three congeners differing only in their side chains attached at C-8 (39) . This is also illustrated in the host strains' ability to produce compounds 4 to 6, as seen in Fig. 3a .
In vivo coexpression of S. lividans TK24 (cosG9B3-U ؊ ) and pRHAM. The deoxysugar plasmid pRHAM is responsible for producing the TDP-activated 6-deoxy-hexopyranose, TDP-Lrhamnose (structure 27) (33). In comparison with pLN2, pRHAM lacks the genes responsible for 2-deoxygenation (oleV and oleW) and therefore leads to only a single L-4-ketosugar intermediate. Since all gilvocarcin-type compounds discovered thus far contain 2-hydroxy groups in their sugar moieties, pRHAM encoding a TDP-6-deoxyhexopyranose was considered a more conservative attempt to modify the gilvocarcin (Fig. 3c) . As before, large-scale fermentation and preparative HPLC were used to isolate all new compounds which were then characterized through NMR and mass spectrometry. Due to poor yields, an 80-liter fermentation of S. lividans TK24 (cosG9B3-U Ϫ /pRHAM) was needed to isolate 4 mg of the major peak, L-rhamnosyl-gilvocarcin M (ϭ polycarcin M; structure 17; ϳ0.05 mg/liter). To simplify future discussions on the growing collection of gilvocarcin analogues, structures 17 and 18 will be referred to as polycarcin M and polycarcin E, as they are congeners of the recently reported polycarcin V (16) . HRMS (MALDI-TOFϩ) of structure 17 gave m/z ϭ 482.1540 ([MϩH] ϩ C 27 H 27 O 8 , requires 482.1499), which was in agreement with the attachment of L-rhamnose. The structure was confirmed by 1 H and 13 C NMR (see Fig. S5 and S6 and Table S7 in the supplemental material), as well as various 2D NMR experiments (COSY, NOESY, HMBC, and HSQC). The sugar moiety, L-rhamnose, was further confirmed through comparisons of reported NMR data from polycarcin V (16).
The remaining minor compounds were identified as polycarcin V (L-rhamnosyl-gilvocarcin; structure 16; ϳ0.03 mg/liter) and polycarcin E (L-rhamnosyl-gilvocarcin E; structure 18; ϳ0.01 mg/liter). The 1 H NMR, 13 C NMR, and HRMS (MALDI-TOFϩ) of structure 16 matched those previously reported for polycarcin V (16) . Due to the limited quantity of structure 18 isolated (Ͻ1 mg) from large fermentations, we relied on APCI mass spectrometry (m/z ϭ 496; [MϩH] ϩ C 27 H 27 O 8 , requires 496.1655) to propose its structure.
The host strain S. lividans TK24 (cosG9B3-U Ϫ ) as well as the two recombinant strains S. lividans TK24 (cosG9B3-U Ϫ / pLN2) and S. lividans TK24 (cosG9B3-U Ϫ /pRHAM) also produced significant amounts of the previously described (17) sugar-free defucogilvocarcins, defucogilvocarcin M (structure 22), defucogilvocarcin V (structure 23), and defucogilvocarcin E (structure 24) (Fig. 3) .
In vivo coexpression of S. lividans TK24 (cosG9B3-U ؊ ) and pLNBIV, pFL942, pKOLV, and pOLO. The deoxysugar plasmids pLNBIV and pFL942 have been shown to direct biosynthesis toward L-digitoxose and L-mycarose, respectively (19, 32) . When these plasmids were used to complement S. lividans TK24 (cosG9B3-U Ϫ ), no new metabolites were observed. This indicates that GilGT is unable to transfer either L-digitoxose or L-mycarose to the gilvocarcin backbone. Similarly, the newly constructed plasmids pKOLV (4-keto-L-olivose) and pOLO (D-oliose) did not yield new products. We anticipated that the removal of oleU (4-ketoreductase) from pLN2 would result in 4-keto-L-olivose while the replacement of oleU with mtmU (4-ketoreductase that forms the axial 4-OH in D-oliose biosynthesis) would result in D-oliose. The products of plasmids pKOLV and pOLO have not yet been verified; therefore, we cannot claim with certainty that the expected sugars were produced. However, based on their derivation from pLN2, a wellestablished deoxysugar plasmid, we hypothesize that GilGT cannot utilize 4-keto-L-olivose or D-oliose.
Bioactivity study. Preliminary anticancer assays against human lung (H460), human breast (MCF-7), and murine lung (LL/2) cancer cell lines using the sulforhodamine B assay (34, 40) indicated that structure 16 has anticancer activity that is comparable to those of structures 2 and 5; however, structure 20 showed slightly better anticancer activity toward cancer cell lines H460 and MCF-7 than structures 2 and 5 (Table 4) . Additionally, dose-dependent curves showed that structures 16 and 20 have 50% growth-inhibitory (GI 50 ) values comparable to (H460) or higher than (MCF-7 and LL/2) that of parent congener structure 2. It should be noted that in all cell lines structure 5 received the lowest GI 50 values (data not shown).
DISCUSSION
The bioactivity of glycosylated natural products produced by actinomycetes, in many cases, can be attributed to their saccharide moiety. Recently, glycodiversification studies have garnered much attention, with the overall goal of generating more bioactive compounds or compounds with improved pharmacological properties (20, 42, 44) . In this study, we chose to probe the donor substrate flexibility of GilGT, the glycosyltransferase involved in gilvocarcin biosynthesis. The recent generation of S. lividans TK24 (cosG9B3-U Ϫ ) provided a suitable model host for probing GilGT flexibility, as cosG9B3-U Ϫ lacks the genes required for the production of the natural D-fucofuranose moiety of the natural gilvocarcins. By expressing deoxysugar plasmids in S. lividans TK24 (cosG9B3-U Ϫ ), we were able to supply GilGT with alternative donor substrates for glycosylation.
The complementation of S. lividans TK24 (cosG9B3-U Ϫ ) with pLN2 and pRHAM resulted in the production of five novel compounds, including D-olivosyl-gilvocarcins M, V, and E as well as polycarcins M and E. The recently reported polycarcin V was isolated as a natural metabolite from S. polyformus; however, its side chain derivatives were not reported (16) . Here we report the engineered production of polycarcin V as well as its methyl and ethyl side chain congeners.
The engineered D-olivosyl-gilvocarcins discussed here are the first examples of gilvocarcin-type anticancer drugs with a neutral multiply deoxygenated sugar moiety. The finding that D-and not L-olivose was the attached sugar moiety of these compounds was unexpected and surprising, since pLN2 encodes the biosynthetic pathway to TDP-L-olivose. We assume either that the 4-ketoreductase OleU, encoded by pLN2, can lividans before it could be converted to 4-keto-6-deoxy-Lolivose by the 3,5 epimerase OleL. Originally, pLN2 was tested with the flexible glycosyltransferase ElmGT from the elloramycin biosynthetic pathway, which resulted in the exclusive production of L-olivosyl-tetracenomycin C (32). In the presence of ElmGT, a GT which naturally transfers L-rhamnose, the biosynthetic pathway favored the production of NDP-Lolivose. However, in the gilvocarcin pathway it is clear that L-olivose cannot be utilized by GilGT, which naturally transfers a D-sugar, and instead it scavenges the limited amount of D-olivose produced by pLN2, generating a small flux toward D-olivose and, therefore, isolable amounts of D-olivosyl-gilvocarcins.
The results presented here provide further examples of successful glycodiversification efforts by utilizing deoxysugar plasmids and relying on the (here limited) flexibility of a glycosyltransferase. We have established GilGT as being a moderately flexible glycosyltransferase able to accept its yet-undetermined natural donor substrate D-fucofuranose or D-fucopyranose as well as D-olivose and L-rhamnose. Additionally, this work demonstrates how substrate preference can shift the biosynthetic flux toward an unexpected outcome, further highlighting the intricacies of engineered biosynthetic approaches to produce new natural product analogues. The fact that several other deoxysugar plasmids failed to trigger the production of new gilvocarcins, however, shows that this method of glycodiversification has its limits when being applied to the gilvocarcin biosynthetic pathway. Besides the limited flexibility of GilGT, the apparently narrow substrate specificity of the terminal enzyme of the gilvocarcin pathway, oxidoreductase GilR (12) , may cause problems, and we are currently further investigating this gatekeeper enzyme with the long-term goal to reengineer it toward broader substrate specificity.
